Table 2.
Baseline characteristics of electrical cardioversion (n = 66)
| Antithrombotic therapy, n (%), n = 66 | |
| Direct oral anticoagulants | 49 (74) |
| VKA | 9 (14) |
| Heparin | 7 (11) |
| No antithrombotic therapy | 1 (2) |
| Antiplatelet agents | 6 (9) |
| Type of direct oral anticoagulants, n = 49 | |
| Rivaroxaban | 18 (37) |
| Apixaban | 30 (61) |
| Dabigatran | 1 (2) |
| Antiarrhythmic drugs (n, %) | |
| Amiodarone | 42 (64) |
| Beta‐blockers | 6 (9) |
| DCCV success rate (n = 57) | 50 (88) |
| Immediate complications following DCCV (n, %) | |
| Death | 0 (0) |
| Sinus node dysfunction | 0 (0) |
| Acute stroke | 0 (0) |
DCCV, direct current cardioversion; VKA, vitamin K antagonist.